Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Income from Continuing Operations (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Income from Continuing Operations for 15 consecutive years, with 1186000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations fell 3.13% year-over-year to 1186000.0, compared with a TTM value of 4073000.0 through Sep 2025, up 66.08%, and an annual FY2024 reading of 4812000.0, up 86.7% over the prior year.
  • Income from Continuing Operations was 1186000.0 for Q3 2025 at Alaunos Therapeutics, down from 1040000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 755000.0 in Q4 2024 and bottomed at 22740000.0 in Q3 2021.
  • Average Income from Continuing Operations over 5 years is 8497368.42, with a median of 9064000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations fell 21.68% in 2021, then skyrocketed 90.5% in 2024.
  • Year by year, Income from Continuing Operations stood at 11807000.0 in 2021, then rose by 19.22% to 9538000.0 in 2022, then rose by 16.66% to 7949000.0 in 2023, then surged by 90.5% to 755000.0 in 2024, then tumbled by 57.09% to 1186000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for TCRT at 1186000.0 in Q3 2025, 1040000.0 in Q2 2025, and 1092000.0 in Q1 2025.